

Message

From: **Ex. 6 Personal Privacy (PP)**
Sent: 5/3/2021 5:56:33 PM
To: **Ex. 6 Personal Privacy (PP)**
Subject: RE: PMN delay

Thanks for the update!

From: **Ex. 6 Personal Privacy (PP)**
Sent: Friday, April 30, 2021 7:10 PM
To: **Ex. 6 Personal Privacy (PP)**
Subject: FW: PMN delay

FYI
From: **Ex. 6 Personal Privacy (PP)**
Sent: Friday, April 30, 2021 7:10 PM
To: **Ex. 6 Personal Privacy (PP)**
Cc: **Ex. 6 Personal Privacy (PP)**
Subject: RE: PMN delay

Ex. 6 Personal Privacy (PP)

Thanks for your understanding of the situation. I agree that we should discuss next week.

The HH team is saturated with work and the current staffing changes due to impeding details will affect the HH work. **Ex. 6 Personal Privacy (PP)** is loaded with work.

If you want the team to work on this case, other work will suffer. The risk assessment work for the next 4 months will be significantly delayed due to the staffing changes expected to materialize in the upcoming weeks.

Ex. 6 Personal Privacy (PP)

US EPA's New Chemicals Division
Washington DC, 20460

Ex. 6 Personal Privacy (PP)

From: **Ex. 6 Personal Privacy (PP)**
Sent: Friday, April 30, 2021 7:00 PM
To: **Ex. 6 Personal Privacy (PP)**
Cc: **Ex. 6 Personal Privacy (PP)**
Subject: FW: PMN delay

RAB,

Let's discuss next week about how we manage these requests through RAB. My assumption is that it is not sustainable for me to send you these cases as HOF.

Ex. 6 Personal Privacy (PP)

Ex. 6 Personal Privacy (PP)

New Chemicals Division
USEPA/OCSP/OPPT

Ex. 6 Personal Privacy (PP)

From: Richard E. Engler, Ph.D. <rengler@actagroup.com>

Sent: Friday, April 30, 2021 6:31 PM

To: Ex. 6 Personal Privacy (PP)

Cc: Ex. 6 Personal Privacy (PP); 'Barron, Emily'

<ebarron@guardian.com>; 'Lee, Beth' <Beth.Lee@kochind.com>; 'Bowman, Heather S'

<Heather.Bowman@kochps.com>

Subject: PMN delay

Ex. 6 Personal Privacy (PP)

Guardian submitted P-20-0181 on September 11, 2020. According to EPA's website, the scoping meeting occurred on October 20, 2020. After a discussion with Ex. 6 Personal Privacy (PP) regarding the potential health concerns that OPPT might express in a health report, Guardian prepared an additional explanation of its view that health risk would be minimal; this document was submitted February 2, 2021.

Guardian understands how overworked the New Chemicals Division's health assessors are. If a completed health report is not forthcoming because of other obligations, Guardian would very much like to discuss the health assessor's view of the updated health explanation so that Guardian can address any concerns that remain.

Please advise if Guardian can schedule a teleconference with the PMN review team (especially the health assessor) or when Guardian can expect a health report.

Rich

RICHARD E. ENGLER, PH.D.
DIRECTOR OF CHEMISTRY

ACTA ASIA | EUROPE | THE AMERICAS

2200 Pennsylvania Avenue, NW, Suite 100W | Washington, D.C. 20037
T: 202-557-3808 | F: 202-557-3836 | actagroup.com